Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12062873 | 0.84 | NEU3 (0.41) | NEU3MAPTNPC1RAB9APOLB | |
| SCHEMBL22628682 | 0.81 | NPC1 (0.47) | MAPTNPC1RAB9APOLBKDM4E | |
| SCHEMBL20017609 | 0.80 | KDM4E (0.44) | NEU3MAPTNPC1RAB9APOLB | |
| SCHEMBL28226425 | 0.80 | MAPT (0.59) | NEU3MAPTNPC1RAB9APOLB | |
| SCHEMBL12190515 | 0.78 | ALDH1A1 (0.52) | MAPTNPC1RAB9APOLBALDH1A1 | |
| SCHEMBL6836151 | 0.78 | MAPT (0.62) | MAPTNPC1RAB9APOLBKDM4E | |
| SCHEMBL18503024 | 0.77 | HDAC1 (0.55) | MAPTNPC1RAB9APOLBKDM4E | |
| SCHEMBL3983979 | 0.77 | CA1 (0.55) | MAPTNPC1RAB9APOLBALDH1A1 | |
| SCHEMBL10620579 | 0.77 | CA1 (0.54) | MAPTNPC1RAB9APOLBKDM4E | |
| SCHEMBL3987763 | 0.75 | KDM4E (0.61) | NEU3MAPTNPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109338-B2 | For use in the prophylaxis and the treatment of Picornavirus and human rotavirus infections. | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| EP-1081138-B1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | MARUISHI PHARMA (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20040009977-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1380575-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | Maruishi Pharmaceutical Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-6541470-B1 | Have a potent antiviral activity against picornaviruses and rotaviruses. | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-01 | — | — | US | disclosed |
| EP-1081138-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | Maruishi Pharmaceutical Co., Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009977-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | MAVS, IRF3, EIF2AK2 | NEU3 1853/4885MAPT 3933/4885NPC1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.